WX-671 Serine Protease Inhibition for Blocking Coronavirus Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for coronavirus infections, particularly those caused by SARS-COV-2, are inadequate in effectively reducing viral load and managing severe symptoms such as pneumonia and multi-organ failure.
Innovation Solution
The use of WX-671, in its various enantiomers and isomers, as a serine protease inhibitor, administered orally in the form of upamostat, to inhibit the activity of transmembrane proteases like TMPRSS2, thereby blocking the spike protein-driven entry of the virus into host cells and reducing coronavirus replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for coronavirus infections are used, then treatment is available, but viral load reduction is insufficient and severe symptoms are not effectively managed
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of serine protease inhibitors to create WX-671 with optimized properties. The compound features a specific molecular structure with a piperazine ring, carbonyl group, and aromatic substituents that enhance its ability to inhibit TMPRSS2 and other transmembrane proteases. This structural parameter optimization results in improved viral load reduction effectiveness compared to existing treatments.
2Reliability
If WX-671 is administered to inhibit transmembrane proteases, then viral replication is reduced, but the complexity of the treatment protocol increases
Solution Approach 1:
WX-671 demonstrates universality by effectively inhibiting multiple transmembrane proteases including TMPRSS2, TMPRSS11A, and furin, which are all involved in coronavirus entry and replication. This multi-target inhibition capability allows a single compound to address multiple aspects of viral replication, simplifying the treatment approach while maintaining high effectiveness against viral replication.
3Productivity
If higher doses of WX-671 are administered, then viral load decreases more significantly, but potential side effects may increase
Solution Approach 1:
The patent optimizes the dosage parameters of WX-671 to achieve effective viral load reduction while minimizing cytotoxicity. Clinical dosing ranges from 200-400 mg daily, with the compound demonstrating a favorable therapeutic index. The chemical structure parameters of WX-671, including its specific functional groups and molecular weight, contribute to its selective inhibition of viral proteases over host cell proteases, thereby reducing off-target cytotoxic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
WX-671 demonstrates a significant decrease in viral load by at least 10% and limits cytotoxicity, providing an effective therapeutic option for COVID-19 by inhibiting viral replication and spread.
Implementation Method 1
WX-671, in its various enantiomers and isomers, as a serine protease inhibitor, administered orally in the form of upamostat, to inhibit the activity of transmembrane proteases like TMPRSS2
Data Source
AI summary
The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.